Impulse Dynamics is conducting a Phase II clinical trial to evaluate an implantable device designed to treat heart failure, called Optimizer.

Optimizer™ technology is based on a new method known as Cardiac Contractility Modulation (CCM). CCM is a method for treating failing hearts in which non-excitatory impulses are delivered to the heart during a period of time called the absolute refractory period (ARP). Therefore, these signals do not initiate the heart to beat (like a pacemaker would). Rather, these signals are intended to modify heart cell function for the treatment of heart failure.

Approximately 420 patients in about 50 sites nationwide will be enrolled in this trial. Patients who qualify will undergo surgery similar to putting in a pacemaker.

Recruitment are currenlty being done on major university hospitals across the country. If you would like to participate, or would like more information, check if you meet the eligibility criteria, or email info@impulse-dynamics.com.